PhD Scientific Days 2025

Pathological and Oncological Sciences III.

Characterization and Survival Outcomes of Small Cell Lung Cancer as a Second Primary Cancer: A Comprehensive Analysis

Előadó neve

Dr. Pozonec Mária Dorothea

Neptun code

WMNSLK

Előadó munkahelye

Department of Thoracic Surgery based at the National Institute of Oncology, Semmelweis University, Budapest, Hungary

Előadó telefonszáma

+36203199835

Előadó e-mail címe

pozonec.maria@phd.semmelweis.hu

Az előadás címe

Characterization and Survival Outcomes of Small Cell Lung Cancer as a Second Primary Cancer: A Comprehensive Analysis

Szerző(k) neve és munkahelye

Maria Dorothea Pozonec¹, Debraj Mukhopadhyay², Barbara Borbély³, Róza Berczi⁴, Orsolya Pipek⁵, Veronika Pozonec⁶, Vivien Téglás¹, Bogos Krisztina⁷, Rényi-Vámos Ferenc¹, Zsolt Megyesfalvi⁸, Döme Balázs⁹

1: Department of Thoracic Surgery based at the National Institute of Oncology, Semmelweis University, Budapest, Hungary
2: Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy,
3: George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures
4: Semmelweis University, Faculty of Medicine,Budapest, Hungary
5: Department of Physics of Complex Systems, Eotvos Lorand University (ELTE),Budapest, Hungary
6: Multidisciplinary Center of Head and Neck Tumors, National Institute ofOncology, Budapest, Hungary
7: National Korányi Institute of Pulmonology, Budapest, Hungary
8: Tumorbiology Department, National Korányi Institute of Pulmonology, Budapest, Hungary
9: Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Bemutatás módja

Szóbeli

Szekció

Pathological and Oncological Sciences III.

Language of the presentation

English

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Background:Small cell lung cancer(SCLC) is characterized by rapid growth, high metastatic capacity, and poor survival. Despite the known increase in the incidence of second primary malignancies(SPM), the existing literature provides only a limited insight into the characteristics of patients with SCLC as their SPM, underscoring the need for a comprehensive evaluation

Aims:This study aims to characterize SCLC as a SPM by analyzing patient demographics, prior cancer types, treatment history, and survival outcomes in comparison to first primary SCLC cases

Methods:A multifaceted methodology was used to combine evidence from an in-depth assessment of patient data from our institution, a population-level analysis using the SEER registry, and a systematic analysis of existing literature (PubMed, Medline via Ovid, Scopus).

Results:The distribution of genders among SCLC as the first vs. second primary cancer was significantly different, with a larger proportion of males (68.5% vs. 42.8%) in the SPM group. Patients with second primary SCLC tend to be significantly older (median age 68.5 years vs. 62.0 years). The smoking distribution between first and second primary SCLC patients is not significantly different. The most common previous malignancy for second primary SCLC patients was breast cancer (33.3%), followed by head and neck (16.7%) gastrointestinal- (16.7%), and genitourinary cancers (14.8%), with an additional few cases of other malignancies. Notably, first primary SCLC patients have a significantly longer survival than SPM patients in a univariate analysis. The type of previous malignancy was moderately associated with survival, however neither the type of treatment for the previous malignancy nor the time since the previous tumor does not seem to have an effect on survival

Conclusion:This study contributes to the understanding of this unique subset of SCLC cases, while also raises questions about the potential impact of previous anti-cancer treatments and shared risk factors

Funding:This research was supported by the TKP2021‐EGA‐33 and by the PC2022-II-19/1/2022. BD and ZM were supported by KH130356 to BD, 2020‐1.1.6‐JÖVŐ to BD, ZM, and FB, and FK‐143751 to BD and ZM. BD was supported by FWF I3522,FWF I3977, I4677. ZM by UNKP‐20‐3,UNKP‐21‐3, UNKP-23-5, and by Bolyai Research Scholarship of the Hungarian Academy of Sciences. V.P. supported by UNKP-23-3

University

Semmelweis University

Supervisor

Döme Balázs

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem hagyta jóvá

Előadó

8059

Start

16:30

End

16:45